__NUXT_JSONP__("/drugs/Iodine_I_131_Rituximab", (function(a,b,c,d){return {data:[{drug:{slug:b,emaEpar:[],fdaDrugLabel:[],id:b,nciThesaurus:{casRegistry:a,chebiId:a,chemicalFormula:a,definition:"A radioimmunoconjugate comprised of rituximab, a recombinant chimeric monoclonal antibody directed against the CD20 antigen, and labeled with iodine I 131 with potential antineoplastic activity. The antibody moiety of iodine I 131 rituximab binds to the CD20 antigen thereby delivering cytotoxic iodine I 131 specifically to cancer cells expressing CD20. The CD20 antigen, a hydrophobic transmembrane protein, is expressed on normal pre-B and mature B lymphocytes.",fdaUniiCode:"K2I4B6I9L1",identifier:"C102981",preferredName:c,semanticType:"Pharmacologic Substance",subclassOf:["C129819","C2124"],synonyms:["(131)I-Rituximab","131I-Rituxan",c,"RITUXIMAB I-131"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FIodine_I_131_Rituximab",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("","Iodine_I_131_Rituximab","Iodine I 131 Rituximab","2021-10-30T13:17:19.143Z")));